Literature DB >> 21863255

Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia.

Byung Gil Moon, Yoon Jeon Kim, Young Hee Yoon, Joo Yong Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21863255     DOI： 10.1007/s00417-011-1798-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  9 in total

1.  Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia.

Authors:  Otacílio Oliveira Maia; Maria Teresa Brizzi Chizzotti Bonanomi; Walter Yukihiko Takahashi; Vinícius Paganini Nascimento; Beatriz Sayuri Takahashi
Journal:  Am J Ophthalmol       Date:  2007-08       Impact factor: 5.258

2.  Retinal telangiectasis in adults: fluorescein angiographic findings and treatment by argon laser.

Authors:  A Chopdar
Journal:  Br J Ophthalmol       Date:  1978-04       Impact factor: 4.638

3.  Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.

Authors:  Rodrigo Jorge; Rogério A Costa; Daniela Calucci; Ingrid U Scott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-29       Impact factor: 3.117

4.  Bevacizumab in the treatment of idiopathic macular telangiectasia.

Authors:  Maria-Andreea Gamulescu; Andreas Walter; Helmut Sachs; Horst Helbig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

5.  Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.

Authors:  Peter Charbel Issa; Frank G Holz; Hendrik P N Scholl
Journal:  Ophthalmology       Date:  2007-09       Impact factor: 12.079

6.  Resolution of macular edema in idiopathic juxtafoveal telangiectasis using PDT.

Authors:  Maria G Kotoula; Dimitrios Z Chatzoulis; Constantinos H Karabatsas; Aristoteles Tsiloulis; Evangelia E Tsironi
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2009 Jan-Feb

7.  Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.

Authors:  P Charbel Issa; R P Finger; F G Holz; H P N Scholl
Journal:  Br J Ophthalmol       Date:  2008-07       Impact factor: 4.638

8.  Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.

Authors:  Jaclyn L Kovach; Philip J Rosenfeld
Journal:  Retina       Date:  2009-01       Impact factor: 4.256

9.  Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.

Authors:  Pukhraj Rishi; Ekta Rishi; Daraius Shroff
Journal:  Indian J Ophthalmol       Date:  2009 May-Jun       Impact factor: 1.848
  9 in total
  5 in total

1.  Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.

Authors:  Buğra Karasu; Betul Onal Gunay
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-25       Impact factor: 3.117

2.  Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex).

Authors:  Mohamed Loutfi; Thomas Papathomas; Ahmed Kamal
Journal:  Case Rep Ophthalmol Med       Date:  2014-06-17

3.  EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.

Authors:  Laura Kowalczuk; Alexandre Matet; Ali Dirani; Alejandra Daruich; Aude Ambresin; Irmela Mantel; Richard F Spaide; Natacha Turck; Francine Behar-Cohen
Journal:  Retina       Date:  2017-12       Impact factor: 4.256

4.  CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS.

Authors:  Rie Osaka; Chieko Shiragami; Aoi Ono; Mamoru Kobayashi; Yukari Takasago; Ayana Yamashita; Akitaka Tsujikawa
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

5.  Pars plana vitrectomy combined with focal endolaser photocoagulation for idiopathic macular telangiectasia.

Authors:  Gaku Terauchi; Celso Soiti Matsumoto; Kei Shinoda; Harue Matsumoto; Yutaka Imamura; Emiko Watanabe; Takaaki Kondo; Atsushi Mizota
Journal:  Case Rep Med       Date:  2014-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.